Our science 02
Linker & Chelator Design
Stable in the bloodstream, precise at the tumor.
We are translating our AI expertise into proprietary linker and chelator IP.
Linker models predict plasma stability, activation in the tumor microenvironment, and payload release, and assess manufacturing scalability before synthesis. Chelator designs target multi-isotope compatibility, faster binding kinetics, reduced immunogenicity, and simpler synthesis routes.
Both are optimized for the short half-life of therapeutic isotopes. AI-optimized chelator design is projected to raise radiolabeling yields by 35%.